Safety Information for Diabetes Medicines and Devices
FDA safety-related information, and MedWatch adverse event reporting program are critical in the treatment and care of patients with diabetes. MedWatch alerts provide timely new safety information on human drugs, medical devices, vaccines and other biologics, dietary supplements, and cosmetics. You can report serious problems with human medical products to the Medwatch program.
For additional information, see Medical Device Safety
Animas Corporation 2020 Insulin Infusion Pump: Class I Recall - False Alarm or Warning Sound FDA Drug Safety Communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes MedWatch Safety Alerts for Diabetes-related Drug/Biologic Products Diabetes Drug Product Medication Guides and REMS Safety Review of Avandia (Rosiglitazone) Stronger Heart Warning on Diabetes Drugs[ARCHIVED]
Subscribe to FDA Updates
E-mail lists managed by GovDelivery
- FDA Diabetes Monitor - FDA's Diabetes e-mail list delivers updates on safety and regulatory issues related to diabetes, including product approvals, safety warnings, notices of upcoming public meetings, and notices about proposed regulatory guidances.
- Patient Network News - A twice monthly newsletter containing FDA-related information on a variety of topics, including new product approvals, significant labeling changes, safety warnings, public meetings, and more.
- MedWatch E-list - Clinically important medical product safety alerts, delivered via e-mail and/or SMS text messages.